An analysis of Eli Lilly's stock reveals high premium, overvaluation concerns and a low dividend yield. LLY is rated hold due ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

INDIANAPOLIS–The U.S. Food and Drug Administration has approved Eli Lilly’s new treatment for moderate to severe eczema. It’s ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- the year it was first approved in the U.S. -- some analysts predicted that ...

Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least ...

Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...

Eli Lilly And Co (LLY) stock saw a decline, ending the day at $912.75 which represents a decrease of $-33.56 or -3.55% from the prior close of $946.31. The stock opened at $941.16 and touched a low of ...

The Lilly Pulitzer Sunshine Sale has colorful dresses, fall-friendly cardigans, jumpsuits, pants, and more up to 70 percent ...

Eli Lilly and Company (NYSE:LLY) was a part of 100 hedge fund portfolios at the end of Q2 2024, down from 109 in the previous ...